NASDAQ:ARGX

argenx - ARGX Stock Forecast, Price & News

$402.31

+3.09 (+0.77%)

(As of 12/2/2022 12:00 AM ET)

Add

Compare

Today's Range: $396.00
▼
$405.00
50-Day Range: $343.75
▼
$402.31
52-Week Range: $249.50
▼
$407.93

Volume: 164,412 shs
Average Volume: 245,952 shs
Market Capitalization: $22.26 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $430.14

argenx MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.93 Rating Score
Upside/Downside: 9.6% Upside
$440.92 Price Target
Short Interest: Healthy
1.23% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($15.20) to ($9.71) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

869th out of 1,034 stocks

Biological Products, Except Diagnostic Industry

144th out of 171 stocks

2.5

Analyst's Opinion

Consensus Rating
argenx has received a consensus rating of Buy. The company's average rating score is 2.93, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $440.92, argenx has a forecasted upside of 9.6% from its current price of $402.31.
Amount of Analyst Coverage
argenx has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
1.23% of the outstanding shares of argenx have been sold short.
Short Interest Ratio / Days to Cover
argenx has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in argenx has recently decreased by 3.98%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
argenx does not currently pay a dividend.
Dividend Growth
argenx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARGX.

2.6

News and Social Media Coverage

News Sentiment
argenx has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for argenx this week, compared to 3 articles on an average week.
Search Interest
3 people have searched for ARGX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added argenx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, argenx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.43% of the stock of argenx is held by insiders.
Percentage Held by Institutions
59.75% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for argenx are expected to grow in the coming year, from ($15.20) to ($9.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of argenx is -23.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of argenx is -23.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
argenx has a P/B Ratio of 8.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About argenx (NASDAQ:ARGX) Stock

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Stock News Headlines

November 30, 2022 | markets.businessinsider.com

Argenx To Acquire FDA Priority Review Voucher - Quick Facts

November 22, 2022 | finance.yahoo.com

Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review

November 22, 2022 | finance.yahoo.com

argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

November 22, 2022 | markets.businessinsider.com

Argenx : FDA Accepts BLA For SC Efgartigimod In Generalized Myasthenia Gravis With Priority Review

November 15, 2022 | finance.yahoo.com

Should You Invest in argenx SE (ARGX)?

November 2, 2022 | finance.yahoo.com

Will argenx SE (ARGX) Deliver Solid Performance in Near-Term?

October 27, 2022 | finance.yahoo.com

argenx Reports Third Quarter 2022 Financial Results and Provides Business Update

October 26, 2022 | finance.yahoo.com

Why Earnings Season Could Be Great for argenx (ARGX)

October 20, 2022 | finance.yahoo.com

argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022

October 18, 2022 | benzinga.com

7 Analysts Have This to Say About argenx - argenx (NASDAQ:ARGX) - Benzinga

October 17, 2022 | seekingalpha.com

Immunovant Stock: Capitalizing On Fast Growing FcRn Space With Novel Asset (NASDAQ:IMVT) - Seeking Alpha

October 14, 2022 | finance.yahoo.com

Thrombocytopenia Market Insights, Epidemiology and Market Forecasts, 2032 - Yahoo Finance

October 6, 2022 | finance.yahoo.com

Generalized Myasthenia Gravis Pipeline Assessment Unveils Top Contenders to Challenge Current Market Biologics - New Spherix Report - Yahoo Finance

October 1, 2022 | reuters.com

ARGX.O - argenx SE - ADR | Stock Price & Latest News | Reuters

September 23, 2022 | investors.com

Tom O'Halloran: Are We On The Cusp Of A Bull Market? - Video - IBD - Investor's Business Daily

September 23, 2022 | globenewswire.com

argenx Submits Biologics License Application to U.S. Food - GlobeNewswire

September 21, 2022 | finance.yahoo.com

Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection

September 21, 2022 | streetinsider.com

argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis - StreetInsider.com

September 21, 2022 | globenewswire.com

argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings - GlobeNewswire

September 21, 2022 | finance.yahoo.com

argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis

September 8, 2022 | globenewswire.com

argenx Appoints Camilla Sylvest to Board of Directors - GlobeNewswire

September 8, 2022 | finance.yahoo.com

argenx Appoints Camilla Sylvest to Board of Directors

September 5, 2022 | nasdaq.com

Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year? - Nasdaq

August 31, 2022 | benzinga.com

(ARGX) – argenx to Present at Wells Fargo Healthcare Conference - Benzinga

August 31, 2022 | finance.yahoo.com

argenx to Present at Wells Fargo Healthcare Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Company Calendar

Last Earnings: 10/27/2022
Today: 12/03/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/02/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARGX
CUSIP: N/A
CIK: 1697862
Web: www.argenx.com
Phone: (176) 303-0488
Fax: N/A
Employees: 650
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $440.92
High Stock Price Forecast: $480.00
Low Stock Price Forecast: $340.00
Forecasted Upside/Downside: +6.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.93
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($17.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-408,270,000.00
Net Margins: -295.08%
Pretax Margin: N/A
Return on Equity: -49.53%
Return on Assets: -44.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.07
Quick Ratio: 10.56

Sales & Book Value

Annual Sales: $539.42 million
Price / Sales: 41.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $49.05 per share
Price / Book: 8.20

Miscellaneous

Outstanding Shares: 55,320,000
Free Float: 53,980,000
Market Cap: $22.26 billion
Optionable: Optionable
Beta: 0.79

Key Executives

Mr. Timothy Van Hauwermeiren EMBA (Age 50)
M.B.A., M.Sc., MSc, CEO & Exec. Director
Comp: $1.28M

Prof. Hans de Haard Ir (Age 62)
Ph.D., Co-Founder & Chief Scientific Officer

Mr. Karl Gubitz (Age 52)
Chief Financial Officer

Mr. R. Keith Woods (Age 54)
Chief Operating Officer

Mr. Arjen Lemmen M.Sc. (Age 37)
VP of Corp. Devel. & Strategy

Dr. David L. Lacey M.D. (Age 70)
Advisor
Comp: $19.71k

Ms. Andria Wilk (Age 48)
Global Head of Quality

Mr. Filip Borgions
VP & Global Head of Technical Operations

Ms. Beth DelGiacco
VP and Global Head of Corp. Communications & Investor Relations

Ms. Malini Moorthy (Age 52)
Gen. Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARGX Stock - Frequently Asked Questions

Should I buy or sell argenx stock right now?: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARGX shares.
View ARGX analyst ratings or view top-rated stocks.
What is argenx's stock price forecast for 2023?: 14 equities research analysts have issued 1-year price objectives for argenx's shares. Their ARGX share price forecasts range from $340.00 to $480.00. On average, they anticipate the company's stock price to reach $440.92 in the next twelve months. This suggests a possible upside of 9.6% from the stock's current price.
View analysts price targets for ARGX or view top-rated stocks among Wall Street analysts.
How have ARGX shares performed in 2022?: argenx's stock was trading at $350.19 at the start of the year. Since then, ARGX shares have increased by 14.9% and is now trading at $402.31.
View the best growth stocks for 2022 here.
When is argenx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our ARGX earnings forecast.
How were argenx's earnings last quarter?: argenx SE (NASDAQ:ARGX) posted its earnings results on Thursday, October, 27th. The company reported ($4.26) EPS for the quarter, missing analysts' consensus estimates of ($3.50) by $0.76. The firm had revenue of $146.49 million for the quarter, compared to analysts' expectations of $115.49 million. argenx had a negative net margin of 295.08% and a negative trailing twelve-month return on equity of 49.53%.
What other stocks do shareholders of argenx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?: (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
What is argenx's stock symbol?: argenx trades on the NASDAQ under the ticker symbol "ARGX."
Who are argenx's major shareholders?: argenx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.66%), Artisan Partners Limited Partnership (5.11%), Jennison Associates LLC (2.80%), Bellevue Group AG (1.66%), BlackRock Inc. (1.45%) and Pictet Asset Management SA (0.91%).
How do I buy shares of argenx?: Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is argenx's stock price today?: One share of ARGX stock can currently be purchased for approximately $402.31.
How much money does argenx make?: argenx (NASDAQ:ARGX) has a market capitalization of $22.26 billion and generates $539.42 million in revenue each year. The company earns $-408,270,000.00 in net income (profit) each year or ($17.19) on an earnings per share basis.
How many employees does argenx have?: The company employs 650 workers across the globe.
How can I contact argenx?: argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for the company is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com.

This page (NASDAQ:ARGX) was last updated on 12/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial